Vriglim-VG 1 0.3 Tablet SR
Marketer
Vridam Healthcare Pvt Ltd
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.3mg)
Overview Vriglim-VG 1 0.3 Tablet SR
DiaBeta-Combo 100mg/30mg extended-release tablets are classified as antidiabetic agents. This combination medication treats type 2 diabetes in adults by helping regulate blood glucose. DiaBeta-Combo should be ingested with food, consistently at the same time daily for optimal effectiveness. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continued use is crucial, even with controlled blood sugar, as discontinuation without medical supervision risks elevated glucose levels, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. This medication forms part of a comprehensive diabetes management plan including diet, exercise, and weight management as advised by your doctor. Lifestyle choices significantly impact diabetes control. Hypoglycemia (low blood sugar) is a common side effect, characterized by sweating, dizziness, headache, and tremors. Regular meals and carrying a rapid-acting glucose source (e.g., sugary snacks or juice) are essential preventative measures. Alcohol consumption increases hypoglycemia risk and should be limited. Additional potential side effects include altered taste, nausea, diarrhea, abdominal pain, headache, edema, blurred vision, fractures, and upper respiratory infections. Weight gain may occur. This medication is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Individuals with a history of heart disease should inform their doctor before commencing treatment. Pregnant or lactating women require physician consultation prior to use. Regular blood glucose monitoring and periodic blood tests (including blood cell counts and liver function) are recommended.
Primary Ingredients of Vriglim-VG 1 0.3 Tablet SR
No information provided. A rephrased version cannot be created.
Uses of Vriglim-VG 1 0.3 Tablet SR
Managing type 2 diabetes
Major Benefits of Vriglim-VG 1 0.3 Tablet SR:
Consume this medication precisely as your physician directs, adhering to the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Vriglim-VG 1 0.3mg Extended-Release tablet on an empty stomach.
Common Side effects of Vriglim-VG 1 0.3 Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Vriglim-VG 1 0.3 Tablet SR:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment duration. Ingest the entire tablet whole; avoid chewing, crushing, or fracturing it. Administer Vriglim-VG 1 0.3 Tablet SR on an empty stomach.
How Vriglim-VG 1 0.3 Tablet SR works:
Vriglim-VG 1 0.3mg extended-release tablet contains a triple-action formulation for diabetes management.
SAFETY ADVICE
AlcoholUNSAFE
Combining Vriglim-VG 1 0.3 Tablet SR and alcohol is inadvisable.
PregnancyCONSULT YOUR DOCTOR
Using Vriglim-VG 1 0.3 SR tablets during pregnancy might pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The extended-release Vriglim-VG 1 0.3 mg tablet is likely unsafe for breastfeeding mothers. Available evidence in humans indicates potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Impaired driving may result from excessively low or high blood glucose levels. Refrain from driving if such symptoms arise.
KidneyUNSAFE
The use of Vriglim-VG 1 0.3 mg sustained-release tablets is likely unsafe for individuals with kidney impairment and should be omitted. Medical advice is recommended. Furthermore, its administration is contraindicated in patients exhibiting severe kidney dysfunction.
LiverCAUTION
Patients with liver impairment should use Vriglim-VG 1 0.3 Tablet SR cautiously, potentially requiring dosage modification. A physician's consultation is advised. For individuals with mild to moderate liver disease, Vriglim-VG 1 0.3 Tablet SR should generally begin at a low dosage; its use is contraindicated in those with severe hepatic dysfunction.
What if you forget to take Vriglim-VG 1 0.3 Tablet SR :
Should you forget to take a Vriglim-VG 1 0.3 mg sustained-release tablet, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Vriglim-VG 1 0.3 Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently